These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

896 related items for PubMed ID: 33607967

  • 1. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K, Suzuki A, Shiga T, Minami Y, Arai K, Ashihara K, Shoda M, Hagiwara N.
    BMC Cardiovasc Disord; 2021 Feb 19; 21(1):106. PubMed ID: 33607967
    [Abstract] [Full Text] [Related]

  • 2. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L.
    J Cardiovasc Electrophysiol; 2016 Aug 19; 27(8):953-60. PubMed ID: 27138377
    [Abstract] [Full Text] [Related]

  • 3. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 19; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 4. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA.
    J Cardiovasc Electrophysiol; 2015 May 19; 26(5):547-55. PubMed ID: 25648421
    [Abstract] [Full Text] [Related]

  • 5. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 6. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 01; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 7. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P, Santini D, Musumeci B, Semprini L, Adduci C, Pagannone E, Proietti G, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2014 Nov 01; 25(11):1180-7. PubMed ID: 25066044
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ.
    Circ Arrhythm Electrophysiol; 2020 Oct 01; 13(10):e008123. PubMed ID: 32897759
    [Abstract] [Full Text] [Related]

  • 9. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 01; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 10. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
    Konstantinou DM, Efthimiadis GK, Vassilikos V, Paraskevaidis S, Pagourelias E, Maron BJ, Karvounis H.
    J Cardiovasc Med (Hagerstown); 2016 Jun 01; 17(6):433-9. PubMed ID: 26885981
    [Abstract] [Full Text] [Related]

  • 11. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y, Zhao S, Chen K, Hua W, Su Y, Chen S, Liang Z, Xu W, Zhang S.
    BMC Cardiovasc Disord; 2019 Oct 21; 19(1):230. PubMed ID: 31638918
    [Abstract] [Full Text] [Related]

  • 12. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R, Minami Y, Haruki S, Kanbayashi K, Itani R, Suzuki A, Ejima K, Shiga T, Shoda M, Hagiwara N.
    Int J Cardiol; 2016 Jul 01; 214():419-22. PubMed ID: 27088403
    [Abstract] [Full Text] [Related]

  • 13. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun 01; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 14. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 15. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
    Magnusson P, Gadler F, Liv P, Mörner S.
    Pacing Clin Electrophysiol; 2016 Mar 25; 39(3):291-301. PubMed ID: 26681505
    [Abstract] [Full Text] [Related]

  • 16. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L, Münch J, Dickow J, Lezius S, Willems S, Hoffmann BA, Patten M.
    Clin Res Cardiol; 2018 Feb 25; 107(2):130-137. PubMed ID: 28965260
    [Abstract] [Full Text] [Related]

  • 17. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 25; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 18. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2005 Jul 25; 5(14):1-74. PubMed ID: 23074465
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 25; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 20. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 25; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.